Full-Time
Customer Service Manager
Posted on 9/12/2025
ANI Pharmaceuticals
501-1,000 employees
Develops, manufactures, markets prescription drugs
Compensation Overview
$110k - $150k/yr
Princeton, NJ, USA
In Person
 Customer Experience & Support (2) |
|---|
| , |
- Bachelor’s degree in Business, Supply Chain, Healthcare Administration, or related field required.
- Minimum 5–7 years of progressive customer service/order management experience, with at least 2 years in a supervisory or management capacity
- Pharmaceutical, biotech, medical device, or healthcare distribution experience strongly preferred
- Prior experience managing 3PL partnerships and distribution operations preferred
- In-depth knowledge of pharmaceutical distribution, order management, controlled substances, and traceability requirements
- Strong leadership and people management skills; proven ability to build, motivate, and retain high-performing teams
- Exceptional communication, negotiation, and stakeholder management skills
- Analytical thinker with strong problem-solving abilities; experience driving improvements through data and KPIs
- Proficiency in ERP/order management systems (SAP, Oracle, JD Edwards, or similar) and Microsoft Office Suite
- Familiarity with FDA, DEA, DSCSA, PDMA, and SOX compliance requirements
- Ability to thrive in a fast-paced, regulated, multi-site environment
- Lead, coach, and inspire the Customer Service team to deliver best-in-class support while fostering professional growth and engagement
- Define clear performance goals, establish service-level standards, and regularly review results against key performance metrics
- Champion a culture of accountability, responsiveness, and continuous improvement
- Act as the senior escalation point for complex order inquiries and critical customer issues
- Build and sustain strong, trust-based relationships with customers, including wholesalers, distributors, specialty pharmacies, and healthcare providers
- Ensure consistent, professional communication across all channels (phone, email, EDI, and ordering platforms)
- Oversee account setup, contract pricing validation, and account maintenance to ensure accuracy and compliance
- Direct all aspects of order processing, pricing, allocation, and fulfillment with a focus on accuracy and compliance
- Lead execution of product launches, backorders, recalls, and allocation strategies in close partnership with Supply Chain, Regulatory, and Quality
- Monitor order patterns, identify risks, and proactively address potential supply disruptions
- Serve as the primary point of contact with the company’s 3PL partner, managing warehousing, shipping operations, inventory reconciliation, and distribution performance
- Monitor and enforce service-level agreements (SLAs), escalating issues and driving resolutions
- Collaborate with 3PL and internal stakeholders to identify opportunities for cost savings, efficiency, and improved customer delivery
- Ensure all order management activities meet FDA, DEA, DSCSA, and PDMA requirements
- Oversee compliance with serialization and product traceability under DSCSA
- Maintain accurate, auditable documentation for orders, customer communications, and issue resolution
- Support regulatory inspections and internal/external audits with timely documentation and responses
- Develop and deliver reports on customer service performance, order trends, product availability, and logistics KPIs
- Identify recurring issues and implement corrective and preventive measures to drive customer satisfaction and operational efficiency
- Lead SOP development, system enhancements, and cross-functional process improvement initiatives
- Partner with IT and Finance to optimize ERP/order management workflows and reporting tools
- Pharmaceutical, biotech, medical device, or healthcare distribution experience strongly preferred
- Prior experience managing 3PL partnerships and distribution operations preferred
ANI Pharmaceuticals develops, manufactures, and markets prescription medications, including generic and branded products, that are FDA-approved. Its medicines are produced in regulated facilities and go through standard safety and efficacy testing to meet patient needs. The company sells these products to pharmacies, hospitals, and healthcare providers, using a portfolio that spans generic drugs and specialty branded therapies. What sets ANI apart is its combination of a diversified product lineup with growth through strategic acquisitions to expand its offerings and market reach, rather than relying on a single product area. Its goal is to provide high-quality medicines to patients while continuously expanding its portfolio and market presence through acquisitions and manufacturing capabilities.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Baudette, Minnesota
Founded
1996
Simplify's Take
What believers are saying
- Cortrophin Gel surges 55%–65% to drive 60% of $1.08B–$1.14B 2026 revenue.
- Six new generics launched in 2026, targeting 10–15 total with high margins.
- $15M Harmony Biosciences license validates rare disease expansion strategy.
What critics are saying
- FDA warning letter halts Baudette facility production of oncology generics.
- Medicare blocks Alluvian retina sales, suppressing ophthalmology revenue.
- Teva launches competing Carbamazepine ER, eroding $65M market share.
What makes ANI Pharmaceuticals unique
- Cortrophin Gel dominates ACTH market with $540–$575M 2026 sales.
- U.S.-based manufacturing excels in potent, high-containment generics.
- Rare disease portfolio targets ophthalmology, rheumatology, neurology unmet needs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 25%TD SYNNEX, a global technology distributor serving as a middleman in the IT supply chain, stands out amongst cash-producing companies with a trailing 12-month free cash flow margin of 1.9%. The company has demonstrated strong fundamentals with annual revenue growth of 25.6% over the past five years and a massive revenue base of $65.14 billion. Share buybacks have driven earnings per share growth to 15.6%, outpacing revenue gains over the last two years. In contrast, online insurance marketplace EverQuote faces challenges with high marketing expenses suggesting heavy customer acquisition costs, whilst ANI Pharmaceuticals struggles with a modest revenue base of $883.4 million, declining operating margins, and negative returns on capital indicating failed growth strategies.
ANI Pharmaceuticals announces the launch of Carbamazepine Extended-Release Capsules. ANI Pharmaceuticals, Inc. PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) - ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI's Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol(R). "Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "The launch of Carbamazepine Extended-Release Capsules, another limited competition product, highlights our continued commitment to improving patient access to essential medicines while maintaining the highest standards of quality and compliance." U.S. annual sales for Carbamazepine Extended-Release Capsules total approximately $65 million, based on February 2026 moving annual total (MAT) IQVIA data. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com. Forward-Looking Statements To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company's strategy; its plans with respect to the commercialization and potential sales of the Company's products, including the launch of Carbamazepine Extended-Release Capsules; its efforts to bring limited-competition products to market and ensure that is high-quality products are readily accessible to its customers and patients in need; expansion plans for the Company's Rare Disease, Generics and Brands businesses; and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates.
ANI Pharmaceuticals has received FDA approval and launched Isosorbide Mononitrate Tablet USP in 10mg and 20mg strengths, a generic version of Monoket. The Princeton-based company announced the launch following final approval of its Abbreviated New Drug Application. CEO Nikhil Lalwani said the launch demonstrates ANI's efforts to bring limited-competition products to market whilst ensuring high-quality products remain accessible to customers and patients. He added that the launch reinforces the company's research and development capabilities and operational execution. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing and commercialising therapeutics across three business segments: Rare Disease, Generics and Brands. The company markets products in ophthalmology, rheumatology, nephrology, neurology and pulmonology.
ANI Pharmaceuticals announces FDA approval and launch of Isosorbide Mononitrate Tablet. PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) - ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI's Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket(R). "We are pleased to announce FDA approval and launch of Isosorbide Mononitrate Tablet USP, which highlights our efforts to bring limited-competition products to market and ensure that our high-quality products are readily accessible to our customers and patients in need," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "This launch reinforces the strength of our R&D capabilities and operational execution as well as our commitment to maintaining a steady cadence of new product launches." About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com. Forward-Looking Statements To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company's strategy; its plans with respect to the commercialization and potential sales of the Company's products, including the launch of Isosorbide Mononitrate Tablet, USP; its efforts to bring limited-competition products to market and ensure that is high-quality products are readily accessible to its customers and patients in need; expansion plans for the Company's Rare Disease, Generics and Brands businesses; and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates. Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company's approved products to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; delays and disruptions in the production of the Company's approved products; delays or failure to obtain or maintain approvals by the FDA of the Company's products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company's products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of the Company's manufacturing partners to meet its product demands and timelines; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company's ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; and general business and economic conditions, such as inflationary pressures and geopolitical conditions. More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Relations: Courtney Mogerley, Argot Partners T: 646-368-8014 E: [email protected]
ANI Pharmaceuticals executive Thomas Rowland sold 4,772 shares of common stock on 11 March 2026 at $74.91 per share, according to an SEC filing. The transaction reduced his direct holdings by 11% to 38,730 shares. This marks his second sale on record, following a disposal of 4,975 shares in August. The sale comes as ANI delivered strong financial results, with 2025 revenue reaching $883.37 million, up 43.8% year-over-year, and net income of $78.3 million. Growth was driven primarily by its Rare Disease segment, where Cortrophin Gel revenue surged over 75% annually. ANI develops and markets branded and generic prescription pharmaceuticals across therapeutic areas including controlled substances, oncology products and hormones. Management has guided to revenue exceeding $1 billion for 2026.